6118 Stock Overview
Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Austar Lifesciences Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.24 |
52 Week High | HK$3.18 |
52 Week Low | HK$1.16 |
Beta | 1.07 |
1 Month Change | -26.19% |
3 Month Change | -22.98% |
1 Year Change | -36.08% |
3 Year Change | -76.20% |
5 Year Change | -82.34% |
Change since IPO | -65.27% |
Recent News & Updates
Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump
Feb 12Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues
Dec 22Recent updates
Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump
Feb 12Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues
Dec 22We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt
Sep 28Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden
Mar 31Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Sep 19Is Austar Lifesciences (HKG:6118) A Risky Investment?
Apr 06Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet
Oct 24With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting
Sep 27If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late
May 31Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Mar 31Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?
Mar 01Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Feb 01Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?
Jan 11Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Dec 21Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?
Dec 07Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like
Nov 23Shareholder Returns
6118 | HK Life Sciences | HK Market | |
---|---|---|---|
7D | -16.2% | -3.5% | 0.3% |
1Y | -36.1% | -63.0% | -12.7% |
Return vs Industry: 6118 exceeded the Hong Kong Life Sciences industry which returned -63% over the past year.
Return vs Market: 6118 underperformed the Hong Kong Market which returned -12.7% over the past year.
Price Volatility
6118 volatility | |
---|---|
6118 Average Weekly Movement | 13.7% |
Life Sciences Industry Average Movement | 11.4% |
Market Average Movement | 7.3% |
10% most volatile stocks in HK Market | 14.7% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 6118's share price has been volatile over the past 3 months.
Volatility Over Time: 6118's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 1,838 | Mars Ho | https://www.austar.com.hk |
Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; clean room enclosure, automation control and monitoring systems; and freeze-dryer, sterile filling, and visual inspection equipment, as well as clean utility, powder, and solid equipment and systems.
Austar Lifesciences Limited Fundamentals Summary
6118 fundamental statistics | |
---|---|
Market cap | HK$635.60m |
Earnings (TTM) | -HK$35.30m |
Revenue (TTM) | HK$1.91b |
0.3x
P/S Ratio-18.0x
P/E RatioIs 6118 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6118 income statement (TTM) | |
---|---|
Revenue | CN¥1.76b |
Cost of Revenue | CN¥1.43b |
Gross Profit | CN¥336.05m |
Other Expenses | CN¥368.66m |
Earnings | -CN¥32.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.064 |
Gross Margin | 19.05% |
Net Profit Margin | -1.85% |
Debt/Equity Ratio | 55.5% |
How did 6118 perform over the long term?
See historical performance and comparison